YIH
GTHX

Y-Intercept (HK)’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Y-Intercept (HK)’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,703
Closed -$115K – 2040
2024
Q1 		$115K Buy
26,703
+5,582
+26% +$19.5K 0.01% 1264
2023
Q4 		$64.4K Buy
+21,121
New +$39.7K 0.01% 1138
2023
Q3 		– Sell
-22,855
Closed -$56.9K – 1728
2023
Q2 		$56.9K Buy
+22,855
New +$62.4K 0.01% 1191
2022
Q3 		– Sell
-17,100
Closed -$84K – 1343
2022
Q2 		$84K Buy
+17,100
New +$94.7K 0.01% 725

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Y-Intercept (HK)'s GTHX Position: Q2 2024 in Review

Y-Intercept (HK) sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 26,703 shares — an estimated $115K sold.

Y-Intercept (HK) first reported a position in GTHX in Q2 2022 and held it in 4 quarters. The position peaked at $115K in Q1 2024. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

  • Y-Intercept (HK) reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 26,703 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $115K.
  • Y-Intercept (HK) first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
  • Y-Intercept (HK)'s G1 Therapeutics, Inc. Common Stock position peaked at $115K in Q1 2024.
  • 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Y-Intercept (HK)'s 13F filing for Q2 2024, filed 14 Aug 2024.